Synthesis, structure, and pharmacological evaluation of Co(III) complex containing tridentate Schiff base ligand

Kirubavathy, S. Jone; Velmurugan, R.; Karvembu, Ramasamy; Bhuvanesh, Nattamai; Parameswari, Kandasamy; Chitra, S.

doi:10.1134/s1070328415050048

Cited by 20 publications

(9 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the chiral metal-templated complexes are already used not only in catalysis but also as chirality sensing agents [200][201][202][203] and in biochemistry. [204][205][206][207] There are outstanding future perspectives for this in the field of asymmetric catalysis in that control of reactivity and stereoselectivity can be achieved through choice of metal ions, ligands and counter-ions, holding great promise for fine tuning for a wide range of chiral transformations. We believe that the various approaches discussed here will have a fresh impact on the development of new chiral metal complex catalysts with 'non-innocent' ligands that can operate exclusively as organocatalysts, and where the activation of the substrates will take place in the ligand sphere of the metal-templated complex and the enantioselectivity control will be provided by the chiral environment of the metal complex.…”

Section: Discussionmentioning

confidence: 99%

Enantioselective “organocatalysis in disguise” by the ligand sphere of chiral metal-templated complexes

2021

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Enantioselective “organocatalysis in disguise” by the ligand sphere of chiral metal-templated complexes

2021

View full text Add to dashboard Cite

show abstract

“…[146] On the other hand, Kirubavathy et al synthesized in 2015 the cobalt(III) octahedral complex labelled as Co-06 that contains two Schiff bases and presented it as a candidate drug in the treatment of MCF-7 cell line. The studied compound showed a low IC 50 value (Co-06 < 100 μM), which was determined by the MTT assay after 48 h of treatment, which represents a poor anticancer activity, such results were attributed to the negative effect of cobalt(III) on normal cell processes and the presence of the azomethine group with a high potential to form hydrogen bonds with DNA (149). The cobalt-based coordination complexes in this section present a poor activity compared to analogues that exhibit another transition metal in their structure.…”

Section: Cobalt(ii) Nickel(ii) and Zinc(ii) Compoundsmentioning

confidence: 99%

Transition Metal Complexes with Tridentate Schiff Bases (O N O and O N N) Derived from Salicylaldehyde: An Analysis of Their Potential Anticancer Activity

et al. 2022

View full text Add to dashboard Cite

Although it is known that the first case of cancer was recorded in ancient Egypt around 1600 BC, it was not until 1917 during the First World War and the development of mustard gas that chemotherapy against cancer became relevant; however, its properties were not recognised until 1946 to later be used in patients. In this sense, the use of metallopharmaceuticals in cancer therapy was extensively explored until the 1960s with the discovery of cisplatin and its anticancer activity. From that date to the present, the search for more effective, more selective metallodrugs with fewer side effects has been an area of continuous exploration. Efforts have led to considering a wide variety of metals from the periodic table, mainly from the d-block, as well as a wide variety of organic ligands, preferably with proven biological activity. In this sense, various research groups have found an ideal binder in Schiff bases, since their raw materials are easily accessible, their synthesis conditions are friendly and their denticity can be manipulated. Therefore, in this review, we have explored the anticancer and antitumor activity reported in the literature for coordination complexes of d-block metals coordinated with tridentate Schiff bases (O N O and O N N) derived from salicylaldehyde. For this work, we have used the main scientific databases CCDC® and SciFinder®.

show abstract

“…42 A cobalt(III) complex containing the tridentate Schiff base ligand derived from the reaction of salicylaldehyde and ethylene diamine displayed moderate activity (IC 50 < 100 µM) against human breast cancer cells (MCF-7). 43 Cobalt(III) complexes bearing two [2-(2-hydroxybenzylideneamino)phenol] ligands inhibited HeLa cell growth, but to a lower extent than cisplatin. 44 In contrast, a water soluble, ligand-bridged cobalt(II) coordination polymer containing 2-oxo-1,2-dihydroquinoline-3-carbaldehyde (isonicotinic) hydrazine ligands displayed micromolar toxicities against a panel of cancer cells (HeLa, HEp-2, and A431), comparable to, and in some cases better than, that of cisplatin.…”

Section: Histidine Targeting Co(iii) Schiff Base Complexes and Relate...mentioning

confidence: 99%

Advances in cobalt complexes as anticancer agents

2015

View full text Add to dashboard Cite

The evolution of resistance to traditional platinum-based anticancer drugs has compelled researchers to investigate the cytostatic properties of alternative transition metal-based compounds. The anticancer potential of cobalt complexes has been extensively studied over the last three decades, and much time has been devoted to understanding their mechanisms of action. This perspective catalogues the development of antiproliferative cobalt complexes, and provides an in depth analysis of their mode of action. Early studies on simple cobalt coordination complexes, Schiff base complexes, and cobalt-carbonyl clusters will be documented. The physiologically relevant redox properties of cobalt will be highlighted and the role this plays in the preparation of hypoxia selective prodrugs and imaging agents will be discussed. The use of cobalt-containing cobalamin as a cancer specific delivery agent for cytotoxins will also be described. The work summarised in this perspective shows that the biochemical and biophysical properties of cobalt-containing compounds can be fine-tuned to produce new generations of anticancer agents with clinically relevant efficacies.

show abstract

Synthesis, structure, and pharmacological evaluation of Co(III) complex containing tridentate Schiff base ligand

Cited by 20 publications

References 21 publications

Enantioselective “organocatalysis in disguise” by the ligand sphere of chiral metal-templated complexes

Enantioselective “organocatalysis in disguise” by the ligand sphere of chiral metal-templated complexes

Transition Metal Complexes with Tridentate Schiff Bases (O N O and O N N) Derived from Salicylaldehyde: An Analysis of Their Potential Anticancer Activity

Advances in cobalt complexes as anticancer agents

Contact Info

Product

Resources

About